Dual Incretin Agonist (GLP-1 & GIP) | Advanced Weight Loss, Appetite Suppression & Glycaemic Control | For Research Use Only

Tirzepatide is a revolutionary dual-action peptide that targets both GLP-1 and GIP receptors, offering a powerful mechanism for regulating appetite, fat metabolism, and blood sugar. It has rapidly emerged as one of the most promising compounds for obesity, type 2 diabetes, and insulin resistance research.

Tirzepatide’s dual agonism enhances insulin secretion, reduces glucagon levels, delays gastric emptying, and increases satiety, resulting in greater fat loss and glycaemic control than GLP-1 agonists alone. The 50mg format provides a high-strength option suitable for extended research protocols.

🔍 Key Features

• Dual Receptor Activation: GLP-1 + GIP

• Enhanced Satiety & Appetite Regulation

• Promotes Fat Oxidation & Caloric Deficit

• Improves Insulin Sensitivity & Glycaemic Balance

• Clinically Proven to Outperform Semaglutide in Trials

• Long-Acting Half-Life Ideal for Weekly Protocols

⚙️ Compound Details

• Peptide Name: Tirzepatide

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₀N₆₀O₆₅

• Molecular Weight: ~4813.45 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 50mg per vial

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C, protected from light and moisture

• Reconstitution: Reconstitute with sterile bacteriostatic water (1–2ml recommended)

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Heat, direct light, and freeze-thaw cycles

⚠️ For Research Use Only

Tirzepatide – 50mg is intended solely for laboratory and scientific research purposes. It is not for human consumption, therapeutic use, or clinical applications.